297 related articles for article (PubMed ID: 12871103)
1. Peptides as new inhibitors of HIV-1 reverse transcriptase and integrase.
de Soultrait VR; Desjobert C; Tarrago-Litvak L
Curr Med Chem; 2003 Sep; 10(18):1765-78. PubMed ID: 12871103
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of peptide motifs against HIV-1 reverse transcriptase and integrase.
Andréola ML
Curr Pharm Des; 2009; 15(21):2508-19. PubMed ID: 19601847
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 integrase and RNase H activities as therapeutic targets.
Andréola ML; De Soultrait VR; Fournier M; Parissi V; Desjobert C; Litvak S
Expert Opin Ther Targets; 2002 Aug; 6(4):433-46. PubMed ID: 12223059
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of HIV-1 reverse transcriptase and integrase: classical and emerging therapeutical approaches.
Tarrago-Litvak L; Andreola ML; Fournier M; Nevinsky GA; Parissi V; de Soultrait VR; Litvak S
Curr Pharm Des; 2002; 8(8):595-614. PubMed ID: 11945161
[TBL] [Abstract][Full Text] [Related]
5. Advances in rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase.
Gu SX; Xue P; Ju XL; Zhu YY
Bioorg Med Chem; 2016 Nov; 24(21):5007-5016. PubMed ID: 27658796
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system.
Jármy G; Heinkelein M; Weissbrich B; Jassoy C; Rethwilm A
J Med Virol; 2001 Jul; 64(3):223-31. PubMed ID: 11424108
[TBL] [Abstract][Full Text] [Related]
7. [Advances in novel anti-HIV-1 drugs and drug candidates: 2005-2008].
Zheng PR; Xue H; Xiao ZY; Liu G
Yao Xue Xue Bao; 2010 Feb; 45(2):154-64. PubMed ID: 21351426
[TBL] [Abstract][Full Text] [Related]
8. Evolution of HIV-1 reverse transcriptase and integrase dual inhibitors: Recent advances and developments.
Gill MSA; Hassan SS; Ahemad N
Eur J Med Chem; 2019 Oct; 179():423-448. PubMed ID: 31265935
[TBL] [Abstract][Full Text] [Related]
9. HIV type 1 integrase inhibitors: from basic research to clinical implications.
Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).
Gleenberg IO; Herschhorn A; Hizi A
J Mol Biol; 2007 Jun; 369(5):1230-43. PubMed ID: 17490682
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of 3-hydroxy-3-phenylpropanoate ester–AZT conjugates as potential dual-action HIV-1 Integrase and Reverse Transcriptase inhibitors.
Manyeruke MH; Olomola TO; Majumder S; Abrahams S; Isaacs M; Mautsa N; Mosebi S; Mnkandhla D; Hewer R; Hoppe HC; Klein R; Kaye PT
Bioorg Med Chem; 2015 Dec; 23(24):7521-8. PubMed ID: 26775541
[TBL] [Abstract][Full Text] [Related]
12. Investigation of novel lipid-functionalized PNA monomers as potential HIV-1 non-nucleoside reverse transcriptase and/or integrase inhibitors.
Thomas MG; Maga G; Mouscadet JF; Howarth NM
Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):1063-6. PubMed ID: 18058537
[TBL] [Abstract][Full Text] [Related]
13. New antiretroviral drugs.
Hanson K; Hicks C
Curr HIV/AIDS Rep; 2006 Jul; 3(2):93-101. PubMed ID: 16608666
[TBL] [Abstract][Full Text] [Related]
14. The development of anti-HIV-1 drugs.
Lu XF; Chen ZW
Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
[TBL] [Abstract][Full Text] [Related]
15. In search of authentic inhibitors of HIV-1 integration.
Debyser Z; Cherepanov P; Van Maele B; De Clercq E; Witvrouw M
Antivir Chem Chemother; 2002 Jan; 13(1):1-15. PubMed ID: 12180645
[TBL] [Abstract][Full Text] [Related]
16. Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase.
Wang Z; Tang J; Salomon CE; Dreis CD; Vince R
Bioorg Med Chem; 2010 Jun; 18(12):4202-11. PubMed ID: 20576573
[TBL] [Abstract][Full Text] [Related]
17. [Research progress of dual inhibitors targeting HIV-1 reverse transcriptase and integrase].
Liu H; Zhan P; Liu XY
Yao Xue Xue Bao; 2013 Apr; 48(4):466-76. PubMed ID: 23833931
[TBL] [Abstract][Full Text] [Related]
18. Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy.
Weber J; Vazquez AC; Winner D; Rose JD; Wylie D; Rhea AM; Henry K; Pappas J; Wright A; Mohamed N; Gibson R; Rodriguez B; Soriano V; King K; Arts EJ; Olivo PD; Quiñones-Mateu ME
Antimicrob Agents Chemother; 2011 Aug; 55(8):3729-42. PubMed ID: 21628544
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
Xue P; Lu HH; Zhu YY; Ju XL; Pannecouque C; Zheng XJ; Liu GY; Zhang XL; Gu SX
Bioorg Med Chem Lett; 2017 Apr; 27(8):1640-1643. PubMed ID: 28314598
[TBL] [Abstract][Full Text] [Related]
20. TSAO compounds: the comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase.
Camarasa MJ; San-Félix A; Velázquez S; Pérez-Pérez MJ; Gago F; Balzarini J
Curr Top Med Chem; 2004; 4(9):945-63. PubMed ID: 15134550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
